BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Teschke R, Frenzel C, Wolff A, Eickhoff A, Schulze J. Drug induced liver injury: accuracy of diagnosis in published reports. Annals of Hepatology 2014;13:248-255. [DOI: 10.1016/s1665-2681(19)30888-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Plüß M, Tampe D, Schwörer H, Bremer SCB, Tampe B. Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM. Front Pharmacol 2022;13:966910. [DOI: 10.3389/fphar.2022.966910] [Reference Citation Analysis]
2 Hashmat Z, Channa IS, Safdar M, Ozaslan M, Saeed M, Siddique F, Junejo Y. Adrenergic blocker terazosin potentially suppresses acetaminophen induced-acute liver injury in animal models via CYP2E1 gene. Toxicol Res . [DOI: 10.1007/s43188-021-00116-y] [Reference Citation Analysis]
3 Bai F, Du W, Liu X, Su L, Li Z, Chen T, Ge X, Li Q, Yang H, Song J. A NO-Responsive Ratiometric Fluorescent Nanoprobe for Monitoring Drug-Induced Liver Injury in the Second Near-Infrared Window. Anal Chem 2021;93:15279-87. [PMID: 34748309 DOI: 10.1021/acs.analchem.1c02238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Béquignon OJ, Pawar G, van de Water B, Cronin MT, van Westen GJ. Computational Approaches for Drug-Induced Liver Injury (DILI) Prediction: State of the Art and Challenges. Systems Medicine 2021. [DOI: 10.1016/b978-0-12-801238-3.11535-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Becker MW, Lunardelli MJM, Tovo CV, Blatt CR. Drug and herb-induced liver injury: A critical review of Brazilian cases with proposals for the improvement of causality assessment using RUCAM. Ann Hepatol 2019;18:742-50. [PMID: 31130470 DOI: 10.1016/j.aohep.2019.03.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Narciso-schiavon JL, Delziovo HA, Santos LEB, Shiozawa MBC, Schiavon LL. Recurrent albendazole-induced acute hepatitis. Rev Colomb Gastroenterol 2018;33:473. [DOI: 10.22516/25007440.206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Zhou J, Li Y, Liu X, Long Y, Chen J. LncRNA-Regulated Autophagy and its Potential Role in Drug-Induced Liver Injury. Ann Hepatol 2018;17:355-63. [PMID: 29735795 DOI: 10.5604/01.3001.0011.7381] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
8 Meunier L, Larrey D. Recent Advances in Hepatotoxicity of Non Steroidal Anti-Inflammatory Drugs. Ann Hepatol 2018;17:187-91. [PMID: 29469052 DOI: 10.5604/01.3001.0010.8633] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
9 Teschke R, Danan G. Causality Assessment Methods in Drug-Induced Liver Injury. Methods in Pharmacology and Toxicology 2018. [DOI: 10.1007/978-1-4939-7677-5_27] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
10 Teschke R, Danan G. Prospective Indian Study of DILI with Confirmed Causality Using the Roussel Uclaf Causality Assessment Method (RUCAM): A report of Excellence. Ann Hepatol 2017;16:324-5. [PMID: 28425398 DOI: 10.5604/16652681.1235471] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
11 Teschke R, Andrade RJ. Drug-induced liver injury: expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment. Gastroenterology 2015;148:1271-3. [PMID: 25921378 DOI: 10.1053/j.gastro.2015.04.027] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
12 Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA. Rivaroxaban postmarketing risk of liver injury. J Hepatol 2014;61:293-300. [PMID: 24681117 DOI: 10.1016/j.jhep.2014.03.026] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]